Taken together, these findings suggest that low plasma RBP4 may serve as a broadly applicable prognostic biomarker in maintenance hemodialysis patients, regardless of sex, diabetes status, or underlying renal pathology. This evidence concerns the gene RBP4 and diabetes mellitus.